Double-blind, Randomized, Dose Optimization Trial of Three Doses of Tipranavir Boosted With Low Dose Ritonavir (TPV/RTV) in Multiple Antiretroviral Drug-experienced Subjects


Phase 2
18 Years
N/A
Not Enrolling
Both
HIV Infections

Thank you

Trial Information

Double-blind, Randomized, Dose Optimization Trial of Three Doses of Tipranavir Boosted With Low Dose Ritonavir (TPV/RTV) in Multiple Antiretroviral Drug-experienced Subjects

Inclusion Criteria

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Outcome Measure:

Virologic response after 2 weeks of functional monotherapy

Principal Investigator

Boehringer Ingelheim Study Coordinator

Investigator Role:

Study Chair

Investigator Affiliation:

Boehringer Ingelheim Pharmaceuticals

Authority:

United States: Food and Drug Administration

Study ID:

1182.52

NCT ID:

NCT00275444

Start Date:

March 2002

Completion Date:

August 2003

Related Keywords:

  • HIV Infections
  • HIV Infections
  • Acquired Immunodeficiency Syndrome

Name

Location
Duke University Medical Center Durham, North Carolina  27710
Ohio State University Medical Center Columbus, Ohio  43210
University of Louisville Louisville, Kentucky  40202
Atlanta Va Medical Center Decatur, Georgia  30033
Washington University St. Louis, Missouri  63110
David Geffen School of Medicine at UCLA Los Angeles, California  90095
Wake Forest University Baptist Medical Center Winston-Salem, North Carolina  27157
Boehringer Ingelheim Investigational Site Phoenix, Arizona  
Boehringer Ingelheim Investigational Site Fountain Valley, California  
Living Hope Clinical Trials, Inc. Long Beach, California  
Vincent Lombardi Cancer Center Washington, D.C., District of Columbia  
Therafirst Medical Center Fort Lauderdale, Florida  
1501 N.W. 9th Ave Miami, Florida  
Boehringer Ingelheim Investigational Site Orlando, Florida  
Hillsborough County Health Dept. Tampa, Florida  
Boehringer Ingelheim Investigational Site Atlanta, Georgia  
Mercer University School of Medicine Macon, Georgia  
CORE Center Chicago, Illinois  
Rush-Presbytarian-St Luke's Medical Center Chicago, Illinois  
HIV Outpatient Program (H.O.P) New Orleans, Louisiana  
John's Hopkins University Baltimore, Maryland  
Boehringer Ingelheim Investigational Site Boston, Massachusetts  
Community Research Initiative of New England Springfield, Massachusetts  
University of Michigan Health System Ann Arbor, Michigan  
Boehringer Ingelheim Investigational Site Kansas City, Missouri  
Boehringer Ingelheim Investigational Site Las Vegas, Nevada  
ID Care Hillsborough, New Jersey  
Boehringer Ingelheim Investigational Site Santa Fe, New Mexico  
Albany Medical College Albany, New York  
University of New York at Stony Brook Stony Brook, New York  
Boehringer Ingelheim Investigational Site Huntersville, North Carolina  
Boehringer Ingelheim Investigational Site Oklahoma City, Oklahoma  
Boehringer Ingelheim Investigational Site Columbia, South Carolina  
Boehringer Ingelheim Investigational Site Houston, Texas  
Boehringer Ingelheim Investigational Site Annandale, Virginia